A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512259-19-00

Acronym

DCR-PHXC-204

Enrollment

Registered

2024-09-16

Start date

2021-04-08

Completion date

Unknown

Last updated

2026-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Hyperoxaluria

Brief summary

The absolute and percent change in Pox from Baseline to Day 180.

Detailed description

Absolute and percent change in Pox from Baseline to maximum reduction through Day 180., Change in the hemodialysis or peritoneal dialysis regimen., Change in stone burden identified via ultrasound from Baseline to Day 180., Change in nephrocalcinosis score., Change in cardiac oxalosis.

Interventions

None listed

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The absolute and percent change in Pox from Baseline to Day 180.	—

Secondary

Measure	Time frame
Absolute and percent change in Pox from Baseline to maximum reduction through Day 180., Change in the hemodialysis or peritoneal dialysis regimen., Change in stone burden identified via ultrasound from Baseline to Day 180., Change in nephrocalcinosis score., Change in cardiac oxalosis.	—

Countries

Germany, Italy, Spain

Outcome results